Norma Nacional de Atención Clínica del Cáncer de Cuello Uterino

Objectives

Bolivia’s 2023 National Clinical Care Standard for Cervical Cancer establishes a mandatory, integrated national framework to reduce cervical-cancer morbidity and mortality through health promotion, prevention, early detection, diagnosis, treatment, palliative care, rehabilitation and follow-up. It seeks timely, comprehensive, safe and standardised care across the National Health System, while improving patients’ quality of life.[1][2][3]

• Standardise prevention, screening, diagnostic, treatment, referral, counter-referral and follow-up practices across public, short-term social-security and private health establishments throughout the country.[2][4]
• Prioritise primary prevention through human papillomavirus vaccination under the Expanded Programme on Immunisation, health promotion, risk-factor counselling and community education.[5][6]
• Strengthen secondary prevention by detecting and treating precursor lesions before invasive cancer develops, using cytology, human papillomavirus testing, co-testing and visual inspection with acetic acid according to availability and eligibility.[7][8][9]
• Provide equitable, intercultural and gender-sensitive care that respects patients’ cultural preferences, privacy, dignity and treatment choices, consistent with the Family, Community and Intercultural Health policy.[10][11]
• Deliver stage- and risk-adapted management ranging from treatment of precancerous lesions to surgery, radiotherapy, chemotherapy, fertility-preserving care, management of recurrence and metastasis, and best supportive care.[12][11][13]
• Integrate palliative care from diagnosis onwards to prevent and relieve physical, psychological, social and spiritual suffering among patients and their families.[14][15]

Implementation

Implementation is organised through Bolivia’s Unified Health System and the Family, Community and Intercultural Health model, combining community participation, intersectoral action, interculturality and comprehensive care. The standard assigns services by level of care and capacity, connects facilities through referral and counter-referral, and requires regular review of compliance and clinical records.[16][17][3][4]

• Coordinate national leadership through the Ministry of Health and Sports, its National Cancer Control Programme and the General Directorate of Health Services Networks, within the applicable legal, regulatory and sectoral planning framework.[18][19][20]
• Engage departmental health services, social-security providers overseen by the Authority for the Supervision of Short-Term Social Security, private providers, health facilities, organised communities and Indigenous peoples through the participation arrangements under the Family, Community and Intercultural Health policy.[10][16][1]
• Deliver first-level services for promotion, vaccination, active case-finding, Papanicolaou testing, human papillomavirus testing, visual inspection with acetic acid where available, cryotherapy where appropriate, patient follow-up and referral of suspected cancer or cases beyond local capacity.[5]
• Provide second-level colposcopy, biopsy and management of histologically confirmed high-grade lesions in authorised facilities with adequate capacity, while maintaining case information and receiving patients referred back from higher levels.[5][21]
• Provide third-level diagnostic confirmation, staging, specialised gynaecological and oncological treatment, radiotherapy, pathology, molecular diagnosis, palliative care and referral back to lower-complexity services for continuing follow-up.[21]
• Strengthen functional health-service networks across public, private, traditional-medicine and social-security subsectors, organising human, physical and financial resources and ensuring continuity of care through transfer and counter-referral.[17]
• Build workforce competence through continuous training, updating and development of health personnel across all care levels, including basic palliative-care training for staff caring for women with cervical cancer.[21][14]
• Apply population-based screening with mechanisms to assess coverage, laboratory quality control for cytology, nationally standardised reporting through the Bethesda System, and timely communication of results.[8][22]
• Require facilities to register and notify human papillomavirus and Papanicolaou tests through national health information systems, maintain follow-up information for positive cases, and submit monthly reports for specified screening activities.[9][23]
• Conduct quarterly compliance reviews of the standard, led by the responsible service or facility authority, using a random sample of care from the preceding quarter and producing reports on unmet requirements and continuous-improvement actions.[4]
• Use data-collection and indicator-assessment tools to compare establishments, identify gaps, set work strategies and targets, and monitor screening coverage, diagnostic processes, treatment, preventive measures, referral and follow-up.[4]
• Use the National Cancer Registry under the National Cancer Control Programme as a source of national cancer-incidence information; the source does not specify a budget, costing methodology, financing sources or quantified resource allocations for implementation.[24][3]

Monitoring & Evaluation

The standard establishes a multi-level monitoring and quality-assurance approach for cervical cancer prevention, diagnosis, treatment, follow-up and palliative care. It combines national cancer-registry data, routine service records, screening-result notification, facility-level compliance reviews, clinical documentation and patient follow-up, although many programme-wide targets and accountability arrangements are not fully specified.[24][3][4]

• Use the Population-Based National Cancer Registry, managed by the National Cancer Control Programme under the Ministry of Health and Sports, to provide national cancer-incidence information.[25][24]
• Review compliance with the National Clinical Care Standard quarterly through random sampling of care delivered in the previous quarter, led by the service head, medical head, director or responsible officer and scheduled in the Annual Operating Plan.[4]
• Produce concise compliance reports that identify unmet requirements and their extent, alongside concrete continuous-improvement actions.[4]
• Apply data-collection and indicator-assessment tools to identify service gaps, define strategies and targets, and compare performance between health establishments.[4]
• Monitor screening coverage, follow-up, referrals, diagnostic criteria, complementary examinations, treatment, discharge and counter-referral, and preventive measures.[4]
• Register and notify all human papillomavirus and Papanicolaou tests through national health information systems, and use information and follow-up systems to monitor positive screening results.[9][26]
• Submit monthly screening reports through the system identified as SNIS, record attended cases and samples in clinical histories, and communicate arrangements for receipt of results.[23][27]
• Maintain daily and monthly consolidated records for visual inspection with acetic acid, cryotherapy, referral and follow-up, including age-disaggregated indicators for women aged under 30, 30 to 49, and over 50 years.[28][29]
• Assess screening coverage through population-based mechanisms, ensure laboratory quality control for cytology, and report cytology using the Bethesda System.[8][22]
• Record specimen adequacy, relevant quality elements and complementary-test methods in cytology reports, including computer-assisted analysis where used.[30][31]
• Maintain records linking cytological, colposcopic and histopathological findings for conservatively managed patients, with a 100% correlation target for high-grade squamous intraepithelial lesions or carcinoma in situ.[32][33][34]
• Register suspected cancer cases, biopsies, treatments, referrals and counter-referrals, and ensure laboratories process and communicate cytology, histopathology and human papillomavirus test results promptly.[21]
• Apply specified clinical turnaround and follow-up requirements, including biopsy results within a maximum of 15 days when suspicious colposcopic findings are identified, post-cryotherapy healing assessment after one month, and repeat visual inspection with acetic acid at 12 months.[35][36]
• Follow patients after treatment every three months during the first two years, every six months until five years, and annually thereafter, using physical and pelvic examinations to identify recurrence, second neoplasms, complications and toxicity.[6]
• Use staging, pathological assessment, imaging, intraoperative frozen-section examination and treatment documentation to inform clinical decisions, including assessment of lymph nodes, surgical margins and disease recurrence.[12][37][38]
• Monitor pregnant patients according to disease status, including trimesterly clinical examination and colposcopy for stage IA1 disease and pelvic review every three to four weeks for women delaying treatment or receiving neoadjuvant chemotherapy.[39]
• Monitor palliative-care needs through assessment of physical, emotional, social and spiritual suffering, but no dedicated palliative-care indicator set or reporting structure is specified.[40][15]
• Use Institutional Strategic Plan measures relating to the number of cancer-care normative documents developed and published, disease reduction, and access to the Universal and Free Unified Health System; the supplied material does not provide baselines, targets or reporting schedules for these measures.[41]

Costing & Financing

The standard describes substantial service, equipment, workforce and infrastructure requirements across prevention, screening, diagnosis, treatment, referral and palliative care, but does not provide a costed implementation plan, budget allocations, financing sources, funding gaps or quantified economic assumptions.[17][3][42]

• Require human, physical and financial resources to be organised across first-, second- and third-level establishments through functional health-service networks, without specifying financial allocations.[17]
• Require infrastructure, furniture, equipment, instruments and supplies at all three levels of care to deliver screening and clinical procedures.[42][9]
• Identify resource requirements for conventional cytology, including trained technicians and cytopathologists, microscopy, staining, transport and information systems.[26]
• Identify requirements for human papillomavirus testing, including trained laboratory staff, electricity, test kits, readers, sample transport and, where available, digital result transmission.[26]
• Identify visual-inspection and cryotherapy requirements, including trained personnel, supervision, examination supplies, cryotherapy equipment, liquid nitrogen or other gas supplies, and equipment maintenance.[26][43]
• Recognise that colposcopy, loop electrosurgical excision procedure and specialist oncology services require appropriate infrastructure, equipment, trained personnel and referral capacity, but assign no monetary values.[44][32]
• Identify centralised multidisciplinary programmes and specialised centres as capacity requirements for complex recurrent disease, pelvic surgery and re-irradiation, without a financing mechanism.[45][46]
• Recognise that treatment selection may take account of patients’ economic circumstances and that patients should receive information on anticipated costs, but no tariffs, coverage arrangements or financial-protection measures are specified.[11][47]
• Describe palliative-care services as potentially reducing hospital stays, costly life-sustaining treatments and end-of-life chemotherapy, while protecting patients and families from financial risks; no savings estimate is provided.[14][40]
• Present fewer screening and treatment visits as a means to improve attendance and follow-up and reduce programme costs, without estimating the scale of savings.[48]
• Note that limited resources and lack of interstitial brachytherapy may lead some centres to consider stereotactic body radiotherapy as an alternative, while recognising lower expected local control and non-standardised dose schedules.[49]
• Provide no explicit budget, costing methodology, funding source, resource-mobilisation target, financing gap or economic assumption for national implementation of the clinical standard.[50][24][3]